S Deshayes1, E Liozon2, N Chanson3, K Sacré3, T Moulinet4, C Blanchard-Delaunay5, O Espitia6, M Groh7, M Versini8, T Le Gallou9, J-E Kahn10, V Grobost11, S Humbert12, M Samson13, R Mourot Cottet14, K Mazodier15, A Dartevel16, J Campagne17, A Dumont1, B Bienvenu18, M Lambert19, A Daumas20, D Saadoun21, A Aouba1, H de Boysson22. 1. Department of Internal Medicine and Clinical Immunology, Normandie Univ, UNICAEN, CHU de Caen Normandie, Avenue de la Côte de Nacre, 14000, Caen, France. 2. Department of Internal Medicine, CHU Limoges, Limoges, France. 3. Department of Internal Medicine, Hôpital Bichat, Paris, France. 4. Department of Internal Medicine, Hôpitaux Privés de Metz, Metz, France. 5. Department of Internal Medicine, Centre Hospitalier Georges Renon, Niort, France. 6. Department of Internal Medicine, CHU Nantes, Nantes, France. 7. Department of Internal Medicine, National Referral Center for Hypereosinophilic Syndromes (CEREO), Hôpital Foch, Suresnes, France. 8. Institut Arnault Tzanck, Saint Laurent du Var, France. 9. Department of Internal Medicine, CHU Rennes, Rennes, France. 10. Department of Internal Medicine, Hôpital Ambroise Paré, Boulogne Billancourt, France. 11. Department of Internal Medicine, CHU Estaing, Clermont-Ferrand, France. 12. Department of Internal Medicine, CHU de Besançon, Besançon, France. 13. Department of Internal Medicine and Clinical Immunology, CHU Dijon, Dijon, France. 14. Department of Internal Medicine, Hôpital Civil, Strasbourg, France. 15. Department of Internal Medicine, Hôpital de la Conception, Marseille, France. 16. Department of Internal Medicine, CHU Grenoble, Grenoble, France. 17. Department of Infectious and Systemic Diseases, Hôpital d'Instruction des Armées, Metz, France. 18. Department of Internal Medicine, Hôpital Saint Joseph, Marseille, France. 19. Department of Internal Medicine, CHU de Lille, Lille, France. 20. Department of Geriatric and Internal Medicine, CHU de Marseille, Marseille, France. 21. Department of Internal Medicine, Hôpital Pitié Salpétrière, Paris, France. 22. Department of Internal Medicine and Clinical Immunology, Normandie Univ, UNICAEN, CHU de Caen Normandie, Avenue de la Côte de Nacre, 14000, Caen, France. deboysson-h@chu-caen.fr.
Abstract
INTRODUCTION: Some studies suggest that there is an increased risk of malignancies in giant cell arteritis (GCA). We aimed to describe the clinical characteristics and outcomes of GCA patients with concomitant malignancy and compare them to a GCA control group. METHOD: Patients with a diagnosis of GCA and malignancy and with a maximal delay of 12 months between both diagnoses were retrospectively included in this study and compared to a control group of age-matched (3:1) patients from a multicenter cohort of GCA patients. RESULTS: Forty-nine observations were collected (median age 76 years). Malignancies comprised 33 (67%) solid neoplasms and 16 (33%) clonal hematologic disorders. No over-representation of a particular type of malignancy was observed. Diagnosis of GCA and malignancy was synchronous in 7 (14%) patients, while malignancy succeeded GCA in 29 (59%) patients. Malignancy was fortuitously diagnosed based on abnormalities observed in laboratory tests in 26 patients, based on imaging in 14 patients, and based on symptoms or clinical examination in the nine remaining patients. Two patients had a concomitant relapse of both conditions. When compared to the control group, patients with concomitant GCA and malignancy were more frequently male (p < 0.001), with an altered general state (p < 0.001), and polymyalgia rheumatica (p < 0.01). CONCLUSIONS: This study does not indicate an over-representation of any particular type of malignancy in GCA patients. Initial follow-up dictated by vasculitis may have led to an early identification of malignancy. Nevertheless, GCA male patients with an altered general state and polymyalgia rheumatica might more frequently show concomitant malignancies.
INTRODUCTION: Some studies suggest that there is an increased risk of malignancies in giant cell arteritis (GCA). We aimed to describe the clinical characteristics and outcomes of GCA patients with concomitant malignancy and compare them to a GCA control group. METHOD:Patients with a diagnosis of GCA and malignancy and with a maximal delay of 12 months between both diagnoses were retrospectively included in this study and compared to a control group of age-matched (3:1) patients from a multicenter cohort of GCA patients. RESULTS: Forty-nine observations were collected (median age 76 years). Malignancies comprised 33 (67%) solid neoplasms and 16 (33%) clonal hematologic disorders. No over-representation of a particular type of malignancy was observed. Diagnosis of GCA and malignancy was synchronous in 7 (14%) patients, while malignancy succeeded GCA in 29 (59%) patients. Malignancy was fortuitously diagnosed based on abnormalities observed in laboratory tests in 26 patients, based on imaging in 14 patients, and based on symptoms or clinical examination in the nine remaining patients. Two patients had a concomitant relapse of both conditions. When compared to the control group, patients with concomitant GCA and malignancy were more frequently male (p < 0.001), with an altered general state (p < 0.001), and polymyalgia rheumatica (p < 0.01). CONCLUSIONS: This study does not indicate an over-representation of any particular type of malignancy in GCA patients. Initial follow-up dictated by vasculitis may have led to an early identification of malignancy. Nevertheless, GCA male patients with an altered general state and polymyalgia rheumatica might more frequently show concomitant malignancies.
Authors: Sigurdur Y Kristinsson; Ola Landgren; Jan Samuelsson; Magnus Björkholm; Lynn R Goldin Journal: Haematologica Date: 2010-01-06 Impact factor: 9.941
Authors: Amir Emamifar; Søren Hess; Torkell Ellingsen; Susan Due Kay; Jacob Christian Bang; Oke Gerke; Per Syrak Hansen; Ziba Ahangarani Farahani; Henrik Petersen; Niels Marcussen; Inger Marie Jensen Hansen; Peter Thye Rønn Journal: J Clin Med Date: 2020-12-04 Impact factor: 4.241